Abstract 325P
Background
Axillary level I-II node (ALN) status is used to stratify breast cancer risk and inform systemic therapy decisions. We sought to investigate the association of breast tumour location with ALN involvement, use of chemotherapy, and breast cancer-specific survival (BCSS).
Methods
Patients diagnosed with stage T1-2 M0 breast cancer from 2004 to 2019 were identified from the SEER 17 registries database. Tumour locations were classified as outer quadrant, inner quadrant, or central. Covariates were age, race, median household income, year of diagnosis, tumour size, histology, grade, and ER/PR/HER2 status. Propensity score weighting with Bayesian additive regression trees was used to balance covariates between tumour locations. Doubly robust estimation was then performed with multivariable logistic and Cox regressions to assess the association of tumour location with binary outcomes and BCSS, respectively.
Results
A total of 453,387 patients with a median follow-up of 70 months were eligible for analysis, of whom 293,070 (65%) had outer quadrant tumours, 127,237 (28%) had inner quadrant tumours, and 33,560 (7%) had central tumours. After propensity score weighting, the rates of ALN metastases for outer quadrant, inner quadrant, and central tumours were 28.2%, 20.2%, and 32.6%, respectively. Chemotherapy was given to 38.0%, 36.5%, and 38.8% of patients. Ten-year BCSS were 91.6%, 91.0%, and 90.5%. Compared to outer quadrant tumours, inner quadrant tumours had lower odds of ALN metastases (OR 0.62; 95% CI 0.61-0.63; P<0.001) and central tumours had higher odds (OR 1.30; 95% CI 1.26-1.33; P<0.001). Similarly, inner quadrant tumours had lower odds of receiving chemotherapy (OR 0.90; 95% CI 0.88-0.91; P<0.001) while central tumours had higher odds (OR 1.07; 95% CI 1.04-1.10; P<0.001). BCSS was worse in both inner quadrant (HR 1.07; 95% CI 1.04-1.10; P<0.001) and central (HR 1.10; 95% CI 1.04-1.15; P<0.001) tumours.
Conclusions
The risk of ALN metastases from breast cancer varies with tumour location. Inner quadrant tumours have worse BCSS than outer quadrant tumours despite a lower risk of ALN metastases. Reliance on ALN staging without consideration of tumour location may lead to treatment decisions that are inconsistent with breast cancer risk.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
252P - Adjuvant chemotherapy in T1a/bN0 breast cancer patients with high oncotype DX recurrence scores (RS>25)
Presenter: Daniela Katz
Session: Poster session 02
253P - Is 6-weekly administration of pembrolizumab in combination with chemotherapy for early triple-negative breast cancer safe? A real-world early comparison of q6w versus q3w administration of pembrolizumab in two large cancer centres in the UK
Presenter: Vasileios Angelis
Session: Poster session 02
254P - Effects of delaying adjuvant chemotherapy initiation on clinical outcomes in early triple-negative breast cancer patients
Presenter: Maria Eleni Hatzipanagiotou
Session: Poster session 02
255P - Prognostic stratification capacity of the CPS+EG scoring system in HER2-low and HER2-zero early breast cancer treated with neoadjuvant chemotherapy
Presenter: Nicolas Roussot
Session: Poster session 02
256P - Evolution and risk stratification of adjuvant treatment strategies for early breast cancer: A Chinese perspective based on a national cancer database
Presenter: Ying Fan
Session: Poster session 02
257P - The characteristics of HER2-positive microinvasive breast cancer and the necessity of chemotherapy and anti-HER2 therapy in these patients: A real-world study
Presenter: Bo Lan
Session: Poster session 02
258P - Cost-effectiveness of neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab for high-risk early-stage triple-negative breast cancer in Colombia
Presenter: Ricardo Brugés Maya
Session: Poster session 02
259P - Adjuvant doxorubicin-cyclophosphamide in early-stage breast cancer provides long-term cardiac safety
Presenter: Thiti Susiriwatananont
Session: Poster session 02
260P - Oncology efficacy of gonadotropin-releasing hormone agonist in hormone receptor-positive very young breast cancer patients treated with neoadjuvant chemotherapy
Presenter: Hee Jun Choi
Session: Poster session 02
261P - Dysregulation of immune checkpoint proteins in newly- diagnosed early breast cancer patients undergoing neoadjuvant chemotherapy: A comparison between TNBC and non-TNBC patients
Presenter: Bernardo Rapoport
Session: Poster session 02